Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients
| Autor: | Tania Policastro, Piera Federico, Giuseppina Della Vittoria Scarpati, Francesco Perri, Ciro Imbimbo, Ottavio De Cobelli, Sabino De Placido, Carlo Buonerba, Michele Aieta, Davide Bosso, Nicola Longo, Michela Izzo, Matteo Ferro, Giuseppe Di Lorenzo, Livio Puglia |
|---|---|
| Přispěvatelé: | Buonerba, C, Federico, P, Bosso, D, Puglia, L, Policastro, T, Izzo, M, Perri, F, Vittoria Scarpati, Gd, Ferro, M, Cobelli, Od, DE PLACIDO, Sabino, Aieta, M, Imbimbo, Ciro, Longo, Nicola, Di Lorenzo, G. |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Carboplatin chemistry.chemical_compound Prostate cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Clinical endpoint Enzalutamide Humans Neoplasm Metastasis Etoposide Aged business.industry General Medicine Prostate-Specific Antigen medicine.disease Combined Modality Therapy Prostatic Neoplasms Castration-Resistant Treatment Outcome chemistry Docetaxel Cabazitaxel Neoplasm Grading business Progressive disease medicine.drug |
| Zdroj: | Future oncology (London, England). 10(8) |
| ISSN: | 1744-8301 |
| Popis: | ABSTRACT: Aims: Carboplatin plus etoposide has modest efficacy in docetaxel-pretreated castration-resistant prostate cancer patients. We hypothesized that carboplatin–etoposide could still exert some therapeutic activity after docetaxel, cabazitaxel and either abiraterone or enzalutamide. Patients & methods: We enrolled 15 patients in the first step of a Phase II trial. The target sample size is 46 patients. The primary end point of the study was progression-free survival after 12 weeks. Results: The median progression-free survival was 11 weeks (range: 8–18), while median overall survival was 18 weeks (range: 12–26). Of seven patients with measurable disease, two had a partial response, two showed stable disease and the remaining three had progressive disease as the best radiological response. Five patients were considered progression-free after 12 weeks, prompting continuation of the trial. Conclusion: Our preliminary findings support the hypothesis that carboplatin plus etoposide may yield some clinical benefit in a population of patients who failed all currently approved therapeutic options for prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|